// App-Quantinova.ai

OC 78.3 : HMB-001 – a novel bispecific antibody accumulating and targeting endogenous FVIIa to activated platelets for subcutaneous prophylaxis in multiple bleeding disorders including Glanzmann Thrombasthenia

Researchers

Presenter

  • H. Ostergaard

Principal Investigators

  • M. Zivkovic

  • P. Gandhi

  • M. Kjelgaard-Hansen

  • M. Broberg

  • E. Olsen

  • C. Rea

  • R. Schutgens

  • R. Urbanus

  • J. Faber

Medical Centers

  • Hemab Therapeutics, Copenhagen, Hovedstaden, Denmark

  • Novo Nordisk, Copenhagen, Hovedstaden, Denmark

  • Hemab Therapeutics, London, England, United Kingdom

  • Akebia Therapeutics Inc Cambridge Massachusetts United States

  • Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, the Netherlands, Utrecht, Utrecht, Netherlands

Locations

  • Denmark

  • Netherlands

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Blood/haematological Diseases

Disease

  • Glanzmann thrombasthenia

Biomarkers

  • Activated factor VII

Drug/Treatment

  • rFVIIa

  • FVIII

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved